Health-related quality of life effects of mometasone furoate dry-powder inhaler (MF DPI) in patients with mild to moderate persistent asthma previously using inhaled corticosteroids

R. F. Lockey, P. Abreu, M. Kimel, H. Sacks (Kenilworth, Bethesda, United States Of America)

Source: Annual Congress 2003 - Glucocorticosteroids: an update on their use
Session: Glucocorticosteroids: an update on their use
Session type: Thematic Poster Session
Number: 1834
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. F. Lockey, P. Abreu, M. Kimel, H. Sacks (Kenilworth, Bethesda, United States Of America). Health-related quality of life effects of mometasone furoate dry-powder inhaler (MF DPI) in patients with mild to moderate persistent asthma previously using inhaled corticosteroids. Eur Respir J 2003; 22: Suppl. 45, 1834

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Does health-related quality of life improve with QD and BID dosing of mometasone furoate dry-powder inhaler (MF DPI) in patients with mild to moderate persistent asthma previously using inhaled corticosteroids?
Source: Eur Respir J 2003; 22: Suppl. 45, 283s
Year: 2003

Reduction in oral corticosteroid use with mometasone furoate DPI improves health-related quality of life in patients with severe persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 395s
Year: 2002

Once-daily, evening administration of mometasone furoate dry powder inhaler improves pulmonary function in patients with mild to moderate persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 282s
Year: 2003

Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS)
Source: Eur Respir J 2004; 24: Suppl. 48, 164s
Year: 2004

Health-related quality of life and asthma control in patients treated with budesonide and formoterol in a single inhaler
Source: Eur Respir J 2001; 18: Suppl. 33, 46s
Year: 2001

Once-daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms, and delays exacerbations in patients with COPD previously maintained on ICS
Source: Eur Respir J 2003; 22: Suppl. 45, 4s
Year: 2003

Effects of mometasone furoate dry powder inhaler administered once-daily in the evening on symptom control in mild to moderate asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 282s
Year: 2003

Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 387s
Year: 2002

Budesonide and formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroid in mild-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 159s
Year: 2001

Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS)
Source: Eur Respir J 2002; 20: Suppl. 38, 47s
Year: 2002

Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 33s
Year: 2003

Effects of one year of treatment with mometasone furoate metered dose inhaler (MF-MDI) on growth in children with asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 378s
Year: 2004

Efficacy, safety and cost of using beclomethason dipropionate in patients with persistent moderate bronchial asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 124s
Year: 2004

Clinical efficacy of seretide and beclomethasone dipropionate in patients with corticosteroid-dependent bronchial asthma and quality of life
Source: Eur Respir J 2004; 24: Suppl. 48, 285s
Year: 2004

Early and sustained benefits of budesonide and formoterol in a single inhaler vs fluticasone in moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 157s
Year: 2001

Fluticasone furoate (FF), an inhaled corticosteroid (ICS), demonstrates efficacy in asthma patients symptomatic on moderate doses of ICS therapy
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010

Add-on effects of long-acting beta2-agonists salmeterol inhaler vs tulobuterol patch in adult patients with mild-to-moderate asthma
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013


Efficacy and safety of the new beclomethasone dipropionate/formoterol combination (HFA MDI) vs. budesonide/formoterol (DPI) in moderate to severe persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 434s
Year: 2006

Assessment of the defined daily dose for mometasone furoate dry powder inhaler in persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 33s
Year: 2003